Investors

Learn more at our dedicated Investor site on BioSig.com.

The market of electrical neuromodulation of Central Nervous System keeps growing.

Screen Shot 2021-02-26 at 2.09.46 PM.png

  • Technological disruption and growing opiod epidemic drives the market for spinal cord stimulation

  • However, living with an implant can be limiting, and device-related complications are common

  • It is projected that CNS market will exceed $14.5B by 2029 (CAGR 11.15%)



Screen Shot 2021-02-26 at 2.09.55 PM.png

  • More physicians fall under pressure to prescribe opioid alternatives

  • More patients than ever before get recommend spinal cord stimulation to address chronic pain

Source: Bioelectronic Medicine 2019-2029. IDTechEx report, Dr. Nadia Tsao.


Screen Shot 2021-02-26 at 2.15.23 PM.png

The reach of Peripheral Nerve Stimulation is vast

  • Devices that stimulate PNS are being used and/or tested to treat a wide range of diseases, including ADHA, epilepsy, IBS, autoimmune disease, depressions and stroke.

  • The current market is dominated by vagus nerve stimulation for epilepsy, with many devices for autoimmune and other inflammatory disorders in development, which are forecast t overtake VNS.

  • The market forecast hinges on successful regulatory approvals and sufficient reimbursement .

  • It is expected that such bioelectronic medicine devices will be moved into the first line therapy, particularly in conditions that escalate with time or benefit from early intervention.

  • Devices that stimulate PNS are being used and/or tested to treat a wide range of disease.

Source: Bioelectronic Medicine 2019 – 2029. IDTechEx report, Dr. Nadia Tsao.